| 13.7297 4.32 (45.91%) | 05-04 11:45 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.53  |
1-year : | 19.31 |
| Resists | First : | 14.15 |
Second : | 16.53 |
| Pivot price | 8.93 |
|||
| Supports | First : | 10.29 |
Second : | 7.9 |
| MAs | MA(5) : | 9.98 |
MA(20) : | 8.76 |
| MA(100) : | 7.11 |
MA(250) : | 5.26 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 91.5 |
D(3) : | 82.7 |
| RSI | RSI(14): 89.2 |
|||
| 52-week | High : | 14.15 | Low : | 2.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RLYB ] has closed It is unclear right now based on current values. 133.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.42 - 9.44 | 9.44 - 9.47 |
| Low: | 8.87 - 8.9 | 8.9 - 8.94 |
| Close: | 9.35 - 9.4 | 9.4 - 9.46 |
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Mon, 04 May 2026
Rallybio Corporation Files Form 8-K with SEC Detailing Waiver Agreement and Entity Information - Minichart
Mon, 04 May 2026
Rallybio Receives Termination Fee After Candid Deal Collapse - TipRanks
Mon, 04 May 2026
Rallybio Corp - Candid terminates merger agreement with Rallybio on May 3, 2026 - SEC filing - marketscreener.com
Fri, 24 Apr 2026
[S-4/A] Rallybio Corp Amended Business Combination Registration | RLYB SEC Filing - Form S-4/A - Stock Titan
Mon, 30 Mar 2026
RALLYBIO CORP (NASDAQ:RLYB) Passes Minervini Trend and High Growth Momentum Filters - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 2.86e+006 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 798 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.127e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 888.2 % |
| Return on Equity (ttm) | -30.1 % |
| Qtrly Rev. Growth | 858000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.52 |
| Dividend | 0 |
| Forward Dividend | 1.41e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|